• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    IBN Announces Latest Episode of The BioMedWire Podcast Featuring Harry Simeonidis, President and CEO of Intelligent Bio Solutions Inc.

    6/17/25 8:00:00 AM ET
    $INBS
    Medical/Dental Instruments
    Health Care
    Get the next $INBS alert in real time by email

    AUSTIN, Texas, June 17, 2025 (GLOBE NEWSWIRE) -- via IBN – IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the latest episode of The BioMedWire Podcast as part of its sustained effort to provide specialized content distribution via widespread syndication channels.

    The BioMedWire Podcast delivers dynamic interviews with industry experts at the forefront of pharmaceutical and biotech advancement. The latest episode features Harry Simeonidis, CEO of Intelligent Bio Solutions Inc. (NASDAQ:INBS), a medical technology company delivering intelligent, rapid, non-invasive testing solutions.

    During the interview, Simeonidis provided an overview of Intelligent Bio Solutions' core offering and strategic direction.

    "We bring a unique technology to the drug screening market," he explained. "We have a product that detects drugs from the sweat on the top of your fingertips. It's a whole new way of doing drug screening for people who come to work every single day."

    Simeonidis emphasized the company's rapid expansion, noting early traction in the U.K. and current deployment across roughly 20 countries. "We're a non-invasive technology company expanding globally with a lot of growth and revenue," he said. "We've submitted our FDA application, and once we clear that, we expect to be in the U.S. in the second half of the year."

    He described the fingerprint-based test as faster, simpler and more affordable than traditional methods. "You can screen an employee before they actually start work — within 10 minutes," he noted. "It's a total game changer."

    Looking ahead, Intelligent Bio Solutions aims to scale through partnerships with U.S. distributors and labs. "They know the customers, they have the install base, and they know how to navigate the market," Simeonidis said. "Once we get FDA clearance, we'll increase our marketing campaigns. Once people know about the product, the adoption rate is very fast."

    Join IBN's Carmel Fisher and Harry Simeonidis, President and CEO of Intelligent Bio Solutions, to learn more about the company's entry into the U.S. market, plans for FDA clearance and how its fingerprint-based drug screening platform is reshaping workplace safety.

    To hear the episode and subscribe for future podcasts, visit https://podcast.biomedwire.com

    The latest installment of The BioMedWire Podcast continues to reinforce IBN's commitment to the expansion of its robust network of brands, client partners, followers, and the growing IBN Podcast Series. For more than 18 years, IBN has leveraged this commitment to provide unparalleled distribution and corporate messaging solutions to 500+ public and private companies.

    To learn more about IBN's achievements and milestones via a visual timeline, visit: https://IBN.fm/TimeLine

    About Intelligent Bio Solutions Inc.

    Intelligent Bio Solutions Inc. is a medical technology company delivering intelligent, rapid, non-invasive testing solutions. The company believes that its Intelligent Fingerprinting Drug Screening System will revolutionize portable testing through fingerprint sweat analysis, which has the potential for broader applications in additional fields. Designed as a hygienic and cost-effective system, the test screens for the recent use of drugs commonly found in the workplace, including opiates, cocaine, methamphetamine, and cannabis. With sample collection in seconds and results in under 10 minutes, this technology would be a valuable tool for employers in safety-critical industries. The company's current customer segments outside the U.S. include construction, manufacturing and engineering, transport and logistics firms, drug treatment organizations, and coroners.

    For more information, visit the company's website at www.IBS.inc

    About IBN

    IBN consists of financial brands introduced to the investment public over the course of 18+ years. With IBN, we have amassed a collective audience of millions of social media followers. These distinctive investor brands aim to fulfill the unique needs of a growing base of client-partners. IBN will continue to expand our branded network of highly influential properties, leveraging the knowledge and energy of specialized teams of experts to serve our increasingly diversified list of clients.

    Through our Dynamic Brand Portfolio (DBP), IBN provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) Press Release Enhancement to ensure maximum impact; (4) full-scale distribution to a growing social media audience; (5) a full array of corporate communications solutions; and (6) total news coverage solutions.

    For more information, please visit https://www.InvestorBrandNetwork.com

    Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

    Forward-Looking Statements

    This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company's SEC filings. These risks and uncertainties could cause the company's actual results to differ materially from those indicated in the forward-looking statements.

    Corporate Communications

    IBN

    Austin, Texas

    www.InvestorBrandNetwork.com

    512.354.7000 Office

    [email protected]



    Primary Logo

    Get the next $INBS alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $INBS

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $INBS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Amendment: Chief Financial Officer Sakiris Spiro Kevin was granted 34,500 shares, increasing direct ownership by 10,952% to 34,815 units (SEC Form 4)

      4/A - INTELLIGENT BIO SOLUTIONS INC. (0001725430) (Issuer)

      3/31/25 4:15:27 PM ET
      $INBS
      Medical/Dental Instruments
      Health Care
    • Chief Executive Officer Simeonidis Harry was granted 40,000 shares, increasing direct ownership by 9,804% to 40,408 units (SEC Form 4)

      4 - INTELLIGENT BIO SOLUTIONS INC. (0001725430) (Issuer)

      9/27/24 5:00:16 PM ET
      $INBS
      Medical/Dental Instruments
      Health Care
    • Chief Financial Officer Sakiris Spiro Kevin was granted 34,500 shares, increasing direct ownership by 10,952% to 34,815 units (SEC Form 4)

      4 - INTELLIGENT BIO SOLUTIONS INC. (0001725430) (Issuer)

      9/27/24 5:00:15 PM ET
      $INBS
      Medical/Dental Instruments
      Health Care

    $INBS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Intelligent Bio Solutions and Spjotgard Drive Rapid Adoption of Fingerprint Drug Testing Across Scandinavia

      NEW YORK, June 25, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (NASDAQ:INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, non-invasive drug screening solutions, today announced the success of its ongoing partnership with Spjotgard, an established distributor serving the Scandinavian market. The collaboration is accelerating the adoption of the Intelligent Fingerprinting Drug Screening System across Sweden, Norway, and Denmark, with a growing interest in Finland. Spjotgard, founded in 2021 by a team with deep pharmaceutical expertise, has rapidly developed a strong regional footprint, positioning INBS' fingerprint drug testing technology as it

      6/25/25 8:30:00 AM ET
      $INBS
      Medical/Dental Instruments
      Health Care
    • Intelligent Bio Solutions Launches In-House Fingerprint Drug Testing Across 20+ Sites for Major Australian Waste Operator, Accelerating APAC Expansion

      NEW YORK, June 18, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (NASDAQ:INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced that Managed Waste Service ("MWS"), a leading Australian waste management provider, plans to implement INBS' Intelligent Fingerprinting Drug Screening System across its New South Wales operations, including its land clearing and green waste processing sites. The decision marks MWS's first move into in-house drug testing across multiple locations, with more than 20 sites simultaneously engaged in remote testing operations. MWS plans to conduct pre-employment, random, an

      6/18/25 8:30:00 AM ET
      $INBS
      Medical/Dental Instruments
      Health Care
    • IBN Announces Latest Episode of The BioMedWire Podcast Featuring Harry Simeonidis, President and CEO of Intelligent Bio Solutions Inc.

      AUSTIN, Texas, June 17, 2025 (GLOBE NEWSWIRE) -- via IBN – IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the latest episode of The BioMedWire Podcast as part of its sustained effort to provide specialized content distribution via widespread syndication channels. The BioMedWire Podcast delivers dynamic interviews with industry experts at the forefront of pharmaceutical and biotech advancement. The latest episode features Harry Simeonidis, CEO of Intelligent Bio Solutions Inc. (NASDAQ:INBS), a medical technology company delivering intelligent, rapid, non-invasive testing solutions. D

      6/17/25 8:00:00 AM ET
      $INBS
      Medical/Dental Instruments
      Health Care

    $INBS
    SEC Filings

    See more
    • Intelligent Bio Solutions Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

      8-K - INTELLIGENT BIO SOLUTIONS INC. (0001725430) (Filer)

      7/3/25 4:15:34 PM ET
      $INBS
      Medical/Dental Instruments
      Health Care
    • SEC Form S-8 filed by Intelligent Bio Solutions Inc.

      S-8 - INTELLIGENT BIO SOLUTIONS INC. (0001725430) (Filer)

      5/30/25 5:26:11 PM ET
      $INBS
      Medical/Dental Instruments
      Health Care
    • Intelligent Bio Solutions Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - INTELLIGENT BIO SOLUTIONS INC. (0001725430) (Filer)

      5/16/25 8:00:18 AM ET
      $INBS
      Medical/Dental Instruments
      Health Care

    $INBS
    Financials

    Live finance-specific insights

    See more
    • Intelligent Bio Solutions Announces Fiscal Q3 2025 Financial Results and Key Operational Achievements

      20% sequential quarterly revenue growth and 91% year-over-year quarterly gross profit growth Continued momentum from recurring higher-margin cartridge sales now reaching 58% of total sales for the nine months ended March 31, 2025  35 new accounts and international growth during Q3 bring total active accounts to over 450 NEW YORK, May 13, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (NASDAQ:INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced its financial results for the fiscal third quarter and nine months ended March 31, 2025, and provided a business update.   The Company delivered a st

      5/13/25 8:30:00 AM ET
      $INBS
      Medical/Dental Instruments
      Health Care
    • Intelligent Bio Solutions Announces Fiscal Q2 2025 Financial Results and Key Operational Achievements

      Gross profit increase of 32.6% and 11-point gross profit margin increase driven by higher-margin cartridge sales Submitted FDA 510(k) and remain on track for planned expansion into multi-billion dollar U.S. market in 2025 Added strategic partnerships, increasing visibility across the Asia-Pacific Region and the U.S. Secured 19 accounts during quarter, adding to 400+ active customer accounts in 19 countries NEW YORK, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (NASDAQ:INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced its financial results for the fiscal second quarter and six

      2/13/25 8:30:00 AM ET
      $INBS
      Medical/Dental Instruments
      Health Care
    • Intelligent Bio Solutions Inc. Reports Fiscal 2024 Fourth Quarter and Full Year Financial Results and Operational Highlights

      - Fourth-quarter revenue of $0.73 million, up 64% year-over-year – - Full-year revenue of $3.11 million, up 148% year-over-year – - As of June 30, 2024, the Company had $6.30 million in cash - NEW YORK, Sept. 19, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (NASDAQ:INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, announced its financial results for the fiscal fourth quarter and full-year ended June 30, 2024, and provided a business update. Fiscal fourth quarter revenue totalled $0.73 million, an increase of 64% compared to the same period the prior year, and full-year revenue totalled $3.11 million,

      9/19/24 8:30:00 AM ET
      $INBS
      Medical/Dental Instruments
      Health Care

    $INBS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Intelligent Bio Solutions Inc.

      SC 13G/A - INTELLIGENT BIO SOLUTIONS INC. (0001725430) (Subject)

      11/14/24 7:16:17 PM ET
      $INBS
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by Intelligent Bio Solutions Inc.

      SC 13G - INTELLIGENT BIO SOLUTIONS INC. (0001725430) (Subject)

      11/14/24 4:31:30 PM ET
      $INBS
      Medical/Dental Instruments
      Health Care